Dose-Response Relationships Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Dose-Response Relationships. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Dose-Response Relationships Indian Medical PG Question 1: What does ED50 measure in pharmacology?
- A. Toxicity
- B. Safety
- C. Potency (Correct Answer)
- D. Efficacy
Dose-Response Relationships Explanation: ***Potency***
- **ED50** (Effective Dose 50%) is the dose of a drug that produces a **therapeutic effect** in 50% of the population or the maximum effect in 50% of subjects [3, 4].
- It is a key measure of a drug's **potency**: a lower ED50 indicates higher potency [1, 3].
*Toxicity*
- **Toxicity** is primarily measured by **LD50** (Lethal Dose 50%), which indicates the dose at which 50% of the population would die [3, 4].
- While related to drug safety, ED50 does not directly quantify toxicity.
*Safety*
- **Safety** is evaluated using the **therapeutic index**, which ideally compares the **TD50** (Toxic Dose 50%) or **LD50** to the ED50 [3, 4].
- ED50 alone measures effectiveness, not the margin between effective and toxic doses.
*Efficacy*
- **Efficacy** refers to the **maximal response** a drug can produce, regardless of the dose [1].
- A drug with high efficacy might have a high or low ED50, as efficacy is about the *height* of the effect, not the *dose* at which it occurs [1].
Dose-Response Relationships Indian Medical PG Question 2: Which of the following statements is true regarding competitive reversible antagonism?
- A. ED50 remains unchanged in competitive reversible antagonism.
- B. Efficacy and Vmax remain unchanged. (Correct Answer)
- C. Potency remains unchanged in the presence of a competitive antagonist.
- D. Affinity (Kd) remains unchanged in competitive reversible antagonism.
Dose-Response Relationships Explanation: ***Efficacy and Vmax remain unchanged.***
- In competitive reversible antagonism, the antagonist binds to the same receptor site as the agonist but can be overcome by increasing the agonist concentration [2]. This means the **maximum effect (efficacy or Vmax)** of the agonist can still be achieved, although a higher dose is needed [2].
- The antagonist does not alter the intrinsic ability of the agonist to produce a full response, only its **apparent affinity** for the receptor.
- This is the hallmark of competitive reversible antagonism: **rightward shift of the dose-response curve with no change in maximum response** [2].
*Potency remains unchanged in the presence of a competitive antagonist.*
- **Potency** is a measure of the amount of drug needed to produce a given effect (often defined by EC50 or ED50) [3].
- A competitive antagonist requires a **higher concentration of agonist** to achieve the same effect, thus **decreasing the apparent potency** of the agonist [4].
- The dose-response curve shifts to the right (parallel shift) [4].
*ED50 remains unchanged in competitive reversible antagonism.*
- **ED50 (effective dose 50)** is the dose that produces 50% of the maximum effect.
- Because competitive antagonists shift the dose-response curve to the right, a **higher ED50** is required to achieve 50% of the maximum effect in the presence of an antagonist [4].
*Affinity (Kd) remains unchanged in competitive reversible antagonism.*
- The **dissociation constant (Kd)** represents the affinity of a drug for its receptor [1].
- In competitive reversible antagonism, the antagonist increases the **apparent Kd** of the agonist (reduces apparent affinity), requiring more agonist to achieve receptor occupancy.
- The **intrinsic Kd** of the agonist doesn't change, but its apparent affinity is reduced due to competition with the antagonist.
Dose-Response Relationships Indian Medical PG Question 3: What does the therapeutic index of a drug signify?
- A. Dose which produces maximum effect
- B. Safety margin (Correct Answer)
- C. Efficacy
- D. Maximum response that can be elicited by a drug
Dose-Response Relationships Explanation: ***Safety margin*** - The **therapeutic index (TI)** is a ratio comparing the dose that produces a toxic effect (TD50 or LD50) to the dose that produces a therapeutically desired effect (ED50) [1]. - A higher therapeutic index indicates a **wider safety margin**, meaning there is a greater difference between the effective and toxic doses [1, 2].*Dose which produces maximum effect* - This describes the **efficacy** of a drug at its maximal point, not its therapeutic index. - The therapeutic index is concerned with the range of doses that can be safely given to achieve a therapeutic effect [2].*Efficacy* - **Efficacy** refers to the maximum effect a drug can produce regardless of the dose. - The therapeutic index is a measure of drug safety, not primarily its efficacy [1].*Maximum response that can be elicited by a drug* - This definition also describes the **efficacy** or **maximal effect** of a drug. - The therapeutic index quantifies the **ratio of toxic to effective doses**, providing insight into safety [1].
Dose-Response Relationships Indian Medical PG Question 4: The therapeutic index of a drug is defined as the ratio between the toxic dose and the effective dose.
- A. Margin of safety
- B. Ratio of toxic dose to effective dose (Correct Answer)
- C. Efficacy of the drug
- D. Drug potency
Dose-Response Relationships Explanation: ***Ratio of toxic dose to effective dose***- The **therapeutic index (TI)** is quantitatively defined as the ratio of the toxic dose (TD50 or LD50) to the effective dose (ED50) [1, 2].- This ratio provides a measure of **drug safety**, indicating the range between the therapeutic and toxic concentrations [1, 3].*Margin of safety*- While related to safety, the **margin of safety** is a different concept, often calculated as (TD1 - ED99) / ED99, focusing on the overlap between very few people experiencing toxicity and almost everyone receiving benefit [2].- The therapeutic index is a broader, simpler ratio that doesn't explicitly guarantee overlap safety but indicates overall drug risk.*Efficacy of the drug*- **Efficacy** refers to the maximal effect a drug can produce regardless of the dose, and it is independent of the therapeutic index [2].- A drug can have high efficacy but a narrow therapeutic index, meaning it is very effective but also very toxic at doses slightly above the therapeutic range.*Drug potency*- **Potency** is the amount of drug needed to produce a given effect (e.g., ED50), reflecting its affinity for receptors and efficiency of action [2].- It is distinct from the therapeutic index, which assesses the separation between desired and undesired effects, not the concentration required to achieve a therapeutic effect.
Dose-Response Relationships Indian Medical PG Question 5: A shift to the right in the biological activity dose- response curve for a hormone with no accompanying change in the maximal response indicates:
- A. Increased sensitivity and decreased responsiveness
- B. Decreased sensitivity (Correct Answer)
- C. Increased responsiveness
- D. Decreased responsiveness and decreased sensitivity
Dose-Response Relationships Explanation: ***Decreased sensitivity***
- A **right shift** in the dose-response curve means a **higher concentration** of the hormone is required to achieve the same effect, indicating reduced sensitivity.
- No change in the **maximal response** implies the system can still reach the same peak effect, but it needs more hormone.
*Increased sensitivity and decreased responsiveness*
- **Increased sensitivity** would be represented by a **left shift** in the dose-response curve, meaning less hormone is needed for a given effect.
- **Decreased responsiveness** implies a reduction in the **maximal effect**, which is stated as unchanged in the question.
*Increased responsiveness*
- **Increased responsiveness** would mean a **higher maximal effect** can be achieved or a steeper slope in the dose-response curve, neither of which is described.
- A right shift is related to the dose required for an effect, not the magnitude of the maximal effect.
*Decreased responsiveness and decreased sensitivity*
- While **decreased sensitivity** is correct, **decreased responsiveness** is incorrect because the question specifies "no accompanying change in the maximal response."
- **Decreased responsiveness** would be indicated by a **lower maximal effect (Emax)**, which is not the case here.
Dose-Response Relationships Indian Medical PG Question 6: What would happen to the half-life and plasma concentration of a drug which follows first-order kinetics, if the dose is doubled?
- A. Half - life and plasma concentration remains the same
- B. Half - life doubles and plasma concentration remains the same
- C. Half - life remains the same and plasma concentration doubles (Correct Answer)
- D. Half - life and plasma concentration doubles
Dose-Response Relationships Explanation: ***Half - life remains the same and plasma concentration doubles***
- In **first-order kinetics**, drug elimination is proportional to the **plasma concentration**, meaning a constant *fraction* of the drug is eliminated per unit of time.
- Doubling the dose will **double the initial plasma concentration**, but the **half-life** (time taken for plasma concentration to halve) remains constant because the *rate of elimination proportionally increases* with concentration.
*Half - life and plasma concentration remains the same*
- This would only be true if the dose was not changed, or if the drug followed **zero-order kinetics** and the elimination system was already saturated, which is not the case here.
- If the plasma concentration remained the same after doubling the dose, it would imply either no absorption or extremely rapid elimination, contradicting typical first-order drug behavior.
*Half - life doubles and plasma concentration remains the same*
- For **half-life to double**, there would need to be a **decrease in drug clearance** or an *increase in volume of distribution*, not simply a dose increase.
- If plasma concentration remained the same despite a doubled dose, it would suggest a **major increase in clearance** or volume of distribution, which is not stated.
*Half life and plasma concentration doubles*
- While plasma concentration doubles with a doubled dose in **first-order kinetics**, the **half-life remains constant**.
- Half-life is an **intrinsic pharmacokinetic parameter** determined by clearance and volume of distribution, not by the administered dose in first-order kinetics.
Dose-Response Relationships Indian Medical PG Question 7: In which phase of clinical trials is drug dosing typically determined?
- A. Phase 1 (Correct Answer)
- B. Phase 2
- C. Phase 3
- D. Phase 4
- E. Phase 0
Dose-Response Relationships Explanation: ***Phase 1***
- This phase involves a small group of **healthy volunteers** to assess the drug's safety, **pharmacokinetics (PK)**, and establish an initial dosing range.
- The primary goal is to determine a **safe dosage level**, establish the **maximum tolerated dose (MTD)**, and identify potential side effects.
- This is where drug dosing is **typically determined**.
*Phase 0*
- This is an exploratory phase involving **microdosing** studies with subtherapeutic doses.
- The goal is to gather preliminary PK/PD data, but **not to determine therapeutic dosing**.
*Phase 2*
- This phase involves a larger group of **patients** with the condition to be treated.
- The main goal is to evaluate the drug's **effectiveness** and further assess safety, but not primarily to determine initial dosing.
*Phase 3*
- This phase involves a large number of patients across multiple sites to confirm the drug's **efficacy** and monitor side effects in a broader population.
- Dosing strategies have generally been established in earlier phases, and this phase primarily validates them.
*Phase 4*
- This phase occurs **after a drug has been approved** and marketed.
- It involves ongoing surveillance to monitor long-term effects, collect additional information on safety, and identify new uses, but not initial dose determination.
Dose-Response Relationships Indian Medical PG Question 8: Which of the following best demonstrates the variability in drug responsiveness among individuals?
- A. Potency
- B. Quantal Dose Response Curve (Correct Answer)
- C. Efficacy
- D. Graded Dose Response Curve
Dose-Response Relationships Explanation: ***Quantal Dose Response Curve***
- A **quantal dose-response curve** plots the percentage of individuals exhibiting a discrete, all-or-none effect against the log dose of a drug.
- This curve directly illustrates the **variability in drug responsiveness** within a population by showing the range of doses required to produce a specific effect in different individuals.
*Efficacy*
- **Efficacy** refers to the maximum effect a drug can produce, regardless of the dose.
- While efficacy is an important pharmacological parameter, it describes the drug's overall therapeutic potential, not the **individual variability** in response.
*Potency*
- **Potency** is a measure of the amount of drug needed to produce an effect of given intensity.
- It relates to the absolute dose required for a particular effect but does not directly demonstrate the **inter-individual differences** in biological response.
*Graded Dose Response Curve*
- A **graded dose-response curve** depicts the relationship between the dose of a drug and the **magnitude of the effect** in a **single biological unit** (e.g., an individual, a tissue, or a cell).
- This curve reflects the relationship between drug concentration and effect intensity, but not the **variability in response among different individuals** in a population.
Dose-Response Relationships Indian Medical PG Question 9: A 70 kg man was given a drug with a dose of 100 mg/kg body weight, twice daily. The half-life (t1/2) is 10 hours, the plasma concentration is 1.9 mg/mL, and the clearance is unknown. What is the clearance of this drug?
- A. 20 liter/hr
- B. K is 0.0693
- C. 0.22 L/hr (Correct Answer)
- D. 0.02 L/hr
Dose-Response Relationships Explanation: ***0.22 L/hr***
- To calculate clearance at steady state, we use the formula: **Clearance (Cl) = Dose Rate / Css** (steady-state plasma concentration).
- **Dose rate calculation**: 100 mg/kg × 70 kg × 2 doses/day = 14,000 mg/day = 583.33 mg/hr
- **Converting plasma concentration**: 1.9 mg/mL = 1900 mg/L
- **Clearance calculation**: Cl = 583.33 mg/hr ÷ 1900 mg/L = **0.307 L/hr**
- **Note**: The calculated value (0.307 L/hr) does not exactly match any option. The marked answer (0.22 L/hr) is the closest approximation among the given choices. This discrepancy may arise from rounding in the original question parameters or implicit assumptions about bioavailability/volume of distribution.
*0.02 L/hr*
- This value is approximately 15 times lower than the calculated clearance.
- Such low clearance would result in much higher plasma concentrations or require significantly lower dosing.
*20 liter/hr*
- This clearance is approximately 65 times higher than calculated, representing an unrealistically high value for this scenario.
- Such high clearance would result in very low plasma concentrations unless extremely high doses were administered.
*K is 0.0693*
- This represents the **elimination rate constant (k)**, calculated as k = 0.693/t1/2 = 0.693/10 hr = 0.0693 hr⁻¹.
- While mathematically correct for k, the question specifically asks for **clearance**, not the elimination rate constant.
- Clearance is related to k by: Cl = k × Vd (volume of distribution).
Dose-Response Relationships Indian Medical PG Question 10: In treatment of Parkinsonism, L-Dopa is combined with carbidopa mainly to:
- A. To decrease dose requirement of L–Dopa
- B. To decrease side effects of L–Dopa (Correct Answer)
- C. To decrease effectiveness of L–Dopa
- D. To increase crossing of L–Dopa through BBB
Dose-Response Relationships Explanation: ***To decrease side effects of L–Dopa***
- This is the **primary/main reason** for combining carbidopa with L-Dopa.
- Carbidopa is a **peripheral DOPA decarboxylase inhibitor**, preventing the conversion of L-Dopa to dopamine in the periphery.
- This reduces side effects like **nausea, vomiting, and cardiac arrhythmias**, which are caused by peripheral dopamine.
- Without carbidopa, peripheral side effects make L-Dopa therapy **intolerable at therapeutic doses**.
*To decrease dose requirement of L–Dopa*
- This is an **important secondary benefit** but not the main reason.
- Carbidopa does allow for **75-80% reduction in L-Dopa dose** (from ~5-6g to ~1g daily) by preventing peripheral metabolism.
- However, this dose reduction is a **consequence** of preventing peripheral conversion, not the primary therapeutic goal.
- The main goal is making L-Dopa therapy **tolerable and safe**, with dose reduction being a beneficial side effect.
*To decrease effectiveness of L–Dopa*
- Carbidopa **increases the effectiveness** of L-Dopa by ensuring more of it reaches the central nervous system to be converted into dopamine.
- By preventing premature peripheral metabolism, carbidopa allows for a greater therapeutic effect on Parkinson's symptoms.
*To increase crossing of L–Dopa through BBB*
- Carbidopa itself **does not cross the blood-brain barrier (BBB)** and therefore does not directly affect the transport of L-Dopa into the brain.
- L-Dopa uses an **active transport system** (large neutral amino acid transporter) to cross the BBB, and carbidopa's role is to prevent its peripheral breakdown before it can utilize this system.
- While more L-Dopa reaches the BBB due to reduced peripheral metabolism, carbidopa does not enhance the actual crossing mechanism.
More Dose-Response Relationships Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
